Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/ II, Multi-center, Open-label Study, to Evaluate the Efficacy of AUY922 in Combination With Lapatinib With Letrozole in Postmenopausal Patients With Locally Advanced or Metastatic ER+ , HER2 + Breast Cancer

NCT01361945 is registered in ClinicalTrials.gov with Texas Tech University Health Sciences Center, El Paso as lead sponsor.

NCT NCT01361945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01361945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/ II, Multi-center, Open-label Study, to Evaluate the Efficacy of AUY922 in Combination With Lapatinib With Letrozole in Postmenopausal Patients With Locally Advanced or Metastatic ER+ , HER2 + Breast Cancer
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Phase
Phase 1/2
Overall status
Withdrawn
Start date
July 31, 2011
Completion date
August 31, 2012
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, er positive breast cancer, her-2 positive breast cancer, metastatic breast cancer